[
  {
    "ts": "2026-02-04T02:49:00+00:00",
    "headline": "Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off",
    "summary": "The company expects to launch more than 20 pivotal late-stage trials this year.",
    "url": "https://www.fool.com/investing/2026/02/03/why-2026-could-be-the-year-pfizers-stock-finally-t/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7554d91e-d731-3faf-bcf8-f55b3dd14c5f",
      "content": {
        "id": "7554d91e-d731-3faf-bcf8-f55b3dd14c5f",
        "contentType": "STORY",
        "title": "Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off",
        "description": "",
        "summary": "The company expects to launch more than 20 pivotal late-stage trials this year.",
        "pubDate": "2026-02-04T02:49:00Z",
        "displayTime": "2026-02-04T02:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Investor at home looking at multiple charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AImvCKGUIyc2oDC.pzXokw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TdGMztVHqpgyf3kAjQrwtw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/03/why-2026-could-be-the-year-pfizers-stock-finally-t/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-2026-could-pfizers-stock-024900212.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T05:13:36+00:00",
    "headline": "Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story",
    "summary": "Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage development program, including more than 20 pivotal studies and multiple Phase 3 trials. The GLP-1 program targets the growing obesity treatment market at a time when Pfizer is addressing revenue pressure from lower COVID-19 product demand and upcoming patent expirations. For you as an investor, this...",
    "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7531535b-ae14-3dc0-a2e9-cc6ae1a0f948",
      "content": {
        "id": "7531535b-ae14-3dc0-a2e9-cc6ae1a0f948",
        "contentType": "STORY",
        "title": "Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage development program, including more than 20 pivotal studies and multiple Phase 3 trials. The GLP-1 program targets the growing obesity treatment market at a time when Pfizer is addressing revenue pressure from lower COVID-19 product demand and upcoming patent expirations. For you as an investor, this...",
        "pubDate": "2026-02-04T05:13:36Z",
        "displayTime": "2026-02-04T05:13:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T06:08:05+00:00",
    "headline": "Pfizer Q4 Earnings Call Highlights",
    "summary": "Pfizer (NYSE:PFE) executives used the company’s fourth-quarter 2025 earnings call to highlight outperformance versus internal commitments, continued progress in recently launched and acquired brands, and a major research update tied to its obesity pipeline. Management also reaffirmed 2026 guidance w",
    "url": "https://www.marketbeat.com/instant-alerts/pfizer-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "41cabc78-4b3d-3dff-bace-5f87a5a1c997",
      "content": {
        "id": "41cabc78-4b3d-3dff-bace-5f87a5a1c997",
        "contentType": "STORY",
        "title": "Pfizer Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) executives used the company’s fourth-quarter 2025 earnings call to highlight outperformance versus internal commitments, continued progress in recently launched and acquired brands, and a major research update tied to its obesity pipeline. Management also reaffirmed 2026 guidance w",
        "pubDate": "2026-02-04T06:08:05Z",
        "displayTime": "2026-02-04T06:08:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Pfizer logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gN0qDzlKmNtqujKAy1Iq7A--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5fyF8KYGugAxs5A_Chyvpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/pfizer-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-q4-earnings-call-highlights-060805182.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T04:09:48+00:00",
    "headline": "Asian shares gained and gold and silver climb higher after a retreat on Wall St",
    "summary": "Asia shares traded mostly higher on Wednesday despite a retreat on Wall Street on selling of technology stocks, while gold and silver continued to regain ground after a recent sell-off. U.S. futures edged higher and oil prices advanced. The future for the S&P 500 edged up 0.2%, while that for the Dow Jones Industrial Average rose 0.3%.",
    "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "4043cad5-ab05-3cad-b585-6048f9af8a8d",
      "content": {
        "id": "4043cad5-ab05-3cad-b585-6048f9af8a8d",
        "contentType": "STORY",
        "title": "Asian shares gained and gold and silver climb higher after a retreat on Wall St",
        "description": "",
        "summary": "Asia shares traded mostly higher on Wednesday despite a retreat on Wall Street on selling of technology stocks, while gold and silver continued to regain ground after a recent sell-off. U.S. futures edged higher and oil prices advanced. The future for the S&P 500 edged up 0.2%, while that for the Dow Jones Industrial Average rose 0.3%.",
        "pubDate": "2026-02-04T04:09:48Z",
        "displayTime": "2026-02-04T04:09:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9",
          "originalWidth": 5258,
          "originalHeight": 3505,
          "caption": "Specialist Anthony Matesic works at his post on the floor of the New York Stock Exchange, Monday, Feb. 2, 2026. (AP Photo/Richard Drew)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/39HZ9JJXKwbFiiUJWDJsXg--~B/aD0zNTA1O3c9NTI1ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9.cf.webp",
              "width": 5258,
              "height": 3505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dmRVvUcSg0IhXfwyFtGEaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "SI=F"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "SFTBF"
            },
            {
              "symbol": "EUR=X"
            },
            {
              "symbol": "ADTTF"
            },
            {
              "symbol": "SSNLF"
            },
            {
              "symbol": "000660.KS"
            },
            {
              "symbol": "^AXJO"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "TOELF"
            },
            {
              "symbol": "NTDOF"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PYPL"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T09:00:00+00:00",
    "headline": "Levicept Announces the Appointment of James Sandy as Chief Development Officer",
    "summary": "Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and d",
    "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b08b841e-1968-3400-8850-8deaf2085284",
      "content": {
        "id": "b08b841e-1968-3400-8850-8deaf2085284",
        "contentType": "STORY",
        "title": "Levicept Announces the Appointment of James Sandy as Chief Development Officer",
        "description": "",
        "summary": "Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and d",
        "pubDate": "2026-02-04T09:00:00Z",
        "displayTime": "2026-02-04T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce",
          "originalWidth": 188,
          "originalHeight": 57,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6mYeXoicbodWtShtPrg.ww--~B/aD01Nzt3PTE4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce.cf.webp",
              "width": 188,
              "height": 57,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MNF0Te8tICDYen70USuKPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T05:32:28+00:00",
    "headline": "PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/pfe-q4-cy2025-deep-dive-053228443.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "5639f924-eea1-3cc0-ab51-04bc7048ea30",
      "content": {
        "id": "5639f924-eea1-3cc0-ab51-04bc7048ea30",
        "contentType": "STORY",
        "title": "PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds",
        "description": "",
        "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.",
        "pubDate": "2026-02-04T05:32:28Z",
        "displayTime": "2026-02-04T05:32:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfe-q4-cy2025-deep-dive-053228443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfe-q4-cy2025-deep-dive-053228443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T09:51:00+00:00",
    "headline": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan",
    "summary": "Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.",
    "url": "https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "07334471-b8eb-34c9-8fd9-d0a7d1034f79",
      "content": {
        "id": "07334471-b8eb-34c9-8fd9-d0a7d1034f79",
        "contentType": "STORY",
        "title": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan",
        "description": "",
        "summary": "Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.",
        "pubDate": "2026-02-04T09:51:00Z",
        "displayTime": "2026-02-04T09:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "People walk by the New York Stock Exchange on February 14, 2023 in New York City.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TUUMCSP7jWZJ_xKWTP11ng--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Mq64gO4UmFCGd0.vo1yfGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/d2f9ee485f2d1d56defe2e03f0780ca3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/earnings-roundup-amgen-vs-fda-095100978.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T16:40:00+00:00",
    "headline": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
    "summary": "Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.",
    "url": "https://www.fool.com/investing/2026/02/04/eli-lilly-soared-2025-healthcare-stock-pfe/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "71fbe66e-91d1-3150-b405-0ded4df7239f",
      "content": {
        "id": "71fbe66e-91d1-3150-b405-0ded4df7239f",
        "contentType": "STORY",
        "title": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
        "description": "",
        "summary": "Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.",
        "pubDate": "2026-02-04T16:40:00Z",
        "displayTime": "2026-02-04T16:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d12847d6af274815373e9ecda3ef306a",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Two people riding a seesaw.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aIKmQABrAMu81ci8jqA1_Q--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d12847d6af274815373e9ecda3ef306a.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ePbXDoP3oCNuwQ9zyE5LWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d12847d6af274815373e9ecda3ef306a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/04/eli-lilly-soared-2025-healthcare-stock-pfe/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-soared-39-2025-164000353.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T15:45:00+00:00",
    "headline": "Biopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global Leaders",
    "summary": "According to Precedence Research, the global biopharmaceutical industry continues to experience robust growth in 2025, with the top 20 companies leading the charge in various therapeutic areas such as oncology, immunology, and vaccines. These industry giants are not only shaping healthcare innovations but also experiencing remarkable revenue growth. The list includes key players such as Merck & Co., Pfizer, and Johnson & Johnson, with each company contributing to the evolution of the biopharma l",
    "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "943eade1-2ab9-3255-bdc6-15097c59e631",
      "content": {
        "id": "943eade1-2ab9-3255-bdc6-15097c59e631",
        "contentType": "STORY",
        "title": "Biopharmaceutical Industry Set for Unprecedented Growth in 2025: Key Trends and Contributions by Global Leaders",
        "description": "",
        "summary": "According to Precedence Research, the global biopharmaceutical industry continues to experience robust growth in 2025, with the top 20 companies leading the charge in various therapeutic areas such as oncology, immunology, and vaccines. These industry giants are not only shaping healthcare innovations but also experiencing remarkable revenue growth. The list includes key players such as Merck & Co., Pfizer, and Johnson & Johnson, with each company contributing to the evolution of the biopharma l",
        "pubDate": "2026-02-04T15:45:00Z",
        "displayTime": "2026-02-04T15:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7",
          "originalWidth": 1667,
          "originalHeight": 1667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2XVm_GDF06LCL8xJEgs9kg--~B/aD0xNjY3O3c9MTY2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 1667,
              "height": 1667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciHBcKYhN1HkkZYm0oIo1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/47160fa420d06f24420d9a27698245a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biopharmaceutical-industry-set-unprecedented-growth-154500153.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T18:11:12+00:00",
    "headline": "Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-announces-positive-phase-181112757.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a0b8707b-3e13-3031-b16a-e8a3eb3aa529",
      "content": {
        "id": "a0b8707b-3e13-3031-b16a-e8a3eb3aa529",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up […]",
        "pubDate": "2026-02-04T18:11:12Z",
        "displayTime": "2026-02-04T18:11:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JdsUG2H00H23uAd7a0c6qw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QqxTp0yGkKMLrei39SQnQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-announces-positive-phase-181112757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-announces-positive-phase-181112757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]